Cell-Penetrating Peptides: 30 Years of Research on Getting Big Drugs Inside Cells | Research

The takeaway

After three decades of development, cell-penetrating peptides remain among the most promising tools for delivering large-molecule drugs into cells, with optimized strategies now reaching clinical trials.

30+ years, still evolving
Cell-penetrating peptides have been studied since the early 1990s and continue to be actively developed with increasingly sophisticated targeting and activation strategies

What the researchers found

After 30+ years of research, cell-penetrating peptides (CPPs) remain one of the most versatile delivery vehicles for macromolecular drugs. The review identifies key optimization strategies: enhanced endosomal escape (overcoming intracellular trapping), extended blood circulation half-life, improved targeting efficiency through tissue-specific modifications, and stimuli-responsive designs that activate only under specific conditions (pH, enzymes, temperature). Clinical trials of CPP-based delivery systems have been conducted, and the review extracts the critical success factors from these trials.

Why it matters

Large molecule drugs (proteins, antibodies, nucleic acids) can't easily get into cells because they're too big to cross the cell membrane. CPPs solve this problem by essentially smuggling cargo across the membrane. This has applications across medicine: delivering gene therapies, getting anti-cancer drugs inside tumor cells, and enabling intracellular delivery of biological drugs that would otherwise be limited to extracellular targets. After decades of research, CPPs are finally maturing toward clinical use.

The numbers in context

30+ years of CPP research · Multiple delivery strategies reviewed · Clinical trials documented · Macromolecular drug delivery (proteins, nucleic acids, etc.)

How the study worked

Comprehensive review article covering CPP development history, classification, cellular uptake mechanisms, biological barriers, optimization strategies, and clinical trial progress for CPP-based macromolecular drug delivery systems.

What this study cannot tell us

This is a review article, not an experimental study. While CPPs show excellent performance in lab settings, in vivo delivery efficiency remains lower due to biological barriers (serum stability, endosomal trapping, off-target distribution). Few CPP-based drugs have achieved clinical approval despite decades of research, suggesting translation challenges that the review acknowledges.

How to read the evidence

This is a comprehensive review article synthesizing decades of CPP research from basic science through clinical trials. It provides a thorough framework rather than new experimental data. The included clinical trial data adds practical relevance.

When this study was published

Published in 2023, this review captures the state of CPP drug delivery at a time when intracellular delivery technologies are of intense interest due to the explosion of RNA, gene, and protein therapeutics.

The bigger picture

CPPs are part of a broader revolution in drug delivery that includes lipid nanoparticles (used in mRNA COVID vaccines), antibody-drug conjugates, and exosomes. Each technology has strengths: LNPs excel at nucleic acid delivery, ADCs at antibody-guided targeting, and CPPs at getting diverse cargo types across cell membranes. As gene and RNA therapies proliferate, the need for efficient intracellular delivery grows. CPPs may find their clinical niche in combination with other delivery technologies rather than as standalone systems.

Questions still open

Why have CPPs struggled to achieve FDA approval after 30 years, and what's the path forward?
Could combining CPPs with lipid nanoparticle technology create superior delivery systems?
Which clinical indications are most likely to see CPP-based drug approvals first?

Common questions

What are cell-penetrating peptides and what do they do?

CPPs are short peptide sequences (typically 5-30 amino acids) that can cross cell membranes — a feat that most large molecules can't achieve. Scientists attach drug cargo to CPPs, essentially using them as molecular delivery trucks to transport large drugs (proteins, DNA, RNA) inside cells where they can work. The first CPP was discovered from the HIV TAT protein in 1988.

If CPPs have been studied for 30 years, why aren't more drugs using them?

The main challenges are: (1) CPPs often get trapped in endosomes (cellular compartments) after entering cells, so the cargo never reaches its target; (2) CPPs lack tissue specificity — they penetrate all cells, not just diseased ones; (3) they get degraded quickly in blood. Recent advances in endosomal escape, targeting strategies, and stimuli-responsive designs are addressing these limitations and bringing CPP-based drugs closer to clinical use.

Read the original research

Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress.

Biomedicines, 11(7)

View on PubMed ↗Publisher’s paper ↗

Citation

Sun, Zhe; Huang, Jinhai; Fishelson, Zvi; Wang, Chenhui; Zhang, Sihe. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress.. Biomedicines, 11(7). https://doi.org/10.3390/biomedicines11071971